Lotte Biologics said on the 1st that it signed an order contract to produce antibodies with a U.S. anticancer corporations. It plans to support clinical trials and commercialization preparations for the antibody therapy at its Syracuse, U.S., plant.
For antibody therapies, the early process is crucial. Lotte Biologics said it is considering not only the production of antibody drug substance but also the subsequent clinical and commercialization stages.
Lotte Biologics is using the Syracuse plant as an overseas base. The company also plans to complete its Songdo bio plant this year. It plans to link the two sites to pursue customer-tailored contract development and manufacturing (CDMO).
A Lotte Biologics official said, "We will work to ensure this leads not only to commercialization with the anticancer corporations but also to additional orders."